Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareSource Yartemlea Prior Auth Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentCareSourcePolicy N/A

    Yartemlea (narsoplimab-wuug) for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA)

    Customize your policy alerts

    Sign up for all CareSource policy alerts

    Know when CareSource releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    CareSource Arkansas PASSE medical prior authorization coverage for Yartemlea in members aged 2 years and older with TA-TMA, including initial authorization, reauthorization, dosing, quantity, exclusion, and treatment-duration requirements.

    Policy Summary
    PayerCareSource
    PolicyYartemlea (narsoplimab-wuug) for TA-TMA
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateOct 1, 2026
    Last ReviewMar 13, 2026
    Next Review DateN/A
    Key ActionSubmit medical prior authorization with documentation of member eligibility, TA-TMA diagnosis, required attestations, and applicable dosing criteria.
    SourceLink
    POLICY UPDATE CHANGES

    A new policy was created to establish coverage criteria for Yartemlea (narsoplimab-wuug) for hematopoietic stem cell transplant-associated thrombotic microangiopathy.

    2 yearsMinimum member age
    4 vials/28 daysQuantity limit
    8 weeksInitial authorization
    16 weeks

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Maximum treatment
    TA-TMACovered indication

    Coverage Criteria

    Initial Therapy

    Yartemlea is covered for initial authorization when ALL applicable requirements are met, including ONE of the two diagnostic pathways.

    ALL of the following

    • Member is at least 2 years of age.
    • Medication is prescribed by or in consultation with a hematologist or transplant specialist.
    • Member is post-hematopoietic stem cell transplant (HSCT).
    • ONE of the following diagnostic pathways

      • TA-TMA is confirmed by renal or intestinal biopsy.

        Documentation must be included in chart notes.

      • ALL of the following

        • Platelet count is less than 150,000/µL.
        • Evidence of microangiopathic hemolysis, demonstrated by the presence of schistocytes, serum LDH greater than the upper limit of normal (ULN), and/or haptoglobin less than the lower limit of normal (LLN).
        • Renal dysfunction.
    • Dosage and quantity limits are met: 4 vials per 28 days; members weighing 50 kg or more receive 370 mg by intravenous infusion once weekly, and members weighing less than 50 kg receive 4 mg/kg by intravenous infusion once weekly.

      Frequency may be increased to twice weekly if there is inadequate improvement in signs and symptoms, subject to reauthorization criteria.

    Continuation and Reauthorization Therapy

    Continuation therapy and reauthorization are covered when ALL required criteria are met. Approval is for an additional 8 weeks, and total treatment duration cannot exceed 16 weeks.

    ALL of the following

    • Chart notes show improvement in platelet count and LDH levels.
    • ONE of the following pathways

      • Standard continuation pathway

        • Chart notes show improvement in organ function.
        • Chart notes show independence from transfusions.
      • For a dose-escalation request, chart notes document inadequate improvement in signs and symptoms, including platelet count, LDH level, organ function, or other relevant clinical findings.

    Coverage requires provider attestation that the member does not have an active infection, a positive direct Coombs test, or Shiga toxin-producing Escherichia coli hemolytic uremic syndrome (STEC-HUS).

    The provider must attest that Yartemlea will not be used in combination with another complement inhibitor.

    Not Medically Necessary

    Yartemlea is not medically necessary for unlisted conditions or indications.

    CareSource considers Yartemlea (narsoplimab-wuug) not medically necessary for the treatment of conditions that are not listed in this policy.

    For any other indication, refer to the Off-Label policy.

    Initial Therapy Criteria

    Initial Authorization

    Initial therapy is covered when all member, diagnostic, exclusion, specialist, and combination-therapy requirements are met.

    Initial authorization

    • Member and specialist criteria: Member is at least 2 years of age, is post-hematopoietic stem cell transplant (HSCT), and Yartemlea is prescribed by or in consultation with a hematologist or transplant specialist.Age ≥ 2 years
    • Diagnostic criteria

      • Biopsy confirmation: TA-TMA is confirmed by renal or intestinal biopsy, with biopsy documentation included in the chart notes.
      • Clinical and laboratory confirmation:

    Continuation and Reauthorization Criteria

    Reauthorization

    Reauthorization may be approved for an additional 8 weeks when the response or dose-escalation requirements are met.

    Continuation therapy

    • Response pathway

      • Laboratory response: Improvement in platelet count and LDH levels.
      • Clinical response: Improvement in organ function or independence from transfusions.
    • Dose-escalation pathway: The request is for dose escalation and chart notes document inadequate improvement in signs and symptoms, such as platelet count, LDH level, or organ function.

    Clinical Thresholds and Dosing Parameters

    Platelet Count
    ThresholdLess than 150,000/µL
    Diagnostic useRequired in the clinical and laboratory pathway for TA-TMA confirmation
    Additional findingsEvaluated with evidence of microangiopathic hemolysis and renal dysfunction
    Serum LDH
    ThresholdGreater than the upper limit of normal (ULN)
    Diagnostic useEvidence of microangiopathic hemolysis in the clinical and laboratory pathway for TA-TMA confirmation
    Related laboratory finding

    Quantity Limits

    Quantity Limits
    MedicationYartemlea (narsoplimab-wuug)
    Quantity limit4 vials per 28 days
    AdministrationIntravenous infusion once weekly; frequency may increase to twice weekly when clinically indicated under reauthorization criteria

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Submit medical prior authorization

    Medical prior authorization is required for Yartemlea. Initial authorization requires all applicable member, prescriber, transplant, diagnostic, exclusion, combination-therapy, and dosing requirements to be satisfied.

    Prior Authorization

    Track authorization duration

    Initial approval is for 8 weeks when criteria are met. Reauthorization may be approved for an additional 8 weeks when response criteria are documented, but total treatment duration cannot exceed 16 weeks.

    • Initial authorization: 8 weeks
    • Reauthorization: an additional 8 weeks
    • Maximum total treatment duration: 16 weeks

    Administration and Site of Care

    Billing Rule

    Administer by the approved infusion schedule

    Administer Yartemlea as an intravenous infusion once weekly. The frequency may increase to twice weekly if there is inadequate improvement in signs and symptoms, subject to reauthorization criteria.

    • Site of care: office
    • Route and frequency: intravenous infusion once weekly
    • Twice-weekly administration may be used when improvement is inadequate

    Clinical Background

    TA-TMA is a multifactorial complication that can occur after hematopoietic stem cell transplantation. It involves endothelial injury, microvascular hemolysis, and complement dysregulation, and may be associated with conditioning regimens, infections including graft-versus-host disease, immunosuppressive therapies, and other transplant complications. Clinical severity may range from mild disease to rapidly progressive end-organ or multiorgan dysfunction and death.

    Definitions

    TA-TMA Definition
    ConditionA multifactorial disorder occurring after hematopoietic stem cell transplantation
    Disease featuresCharacterized by endothelial damage, endothelial injury or activation, and complement dysregulation
    HemolysisMarked by microvascular hemolysis
    MASP-2 Inhibitor
    TermMASP-2 inhibitor
    Full nameMannan-binding lectin-associated serine protease-2 inhibitor
    Policy medicationYartemlea (narsoplimab-wuug) is a MASP-2 inhibitor
    Policy Summary
    PayerCareSource
    PolicyYartemlea (narsoplimab-wuug) for TA-TMA
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateOct 1, 2026
    Last ReviewMar 13, 2026
    Next Review DateN/A
    Key ActionSubmit medical prior authorization with documentation of member eligibility, TA-TMA diagnosis, required attestations, and applicable dosing criteria.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation and Reauthorization CriteriaClinical Thresholds and Dosing ParametersQuantity LimitsAuthorization, Documentation, and Denial RisksAdministration and Site of CareClinical BackgroundDefinitions

    Dose frequency may be increased to twice weekly when inadequate improvement is documented.

    TA-TMA is confirmed by platelet count below 150,000/µL, evidence of microangiopathic hemolysis, and renal dysfunction.
    Platelets < 150,000/µL; schistocytes, serum LDH > ULN and/or haptoglobin < LLN
  1. Exclusion criteria: The provider attests that the member does not have an active infection, positive direct Coombs test, or STEC-HUS.
  2. Combination-therapy criterion: The provider attests that Yartemlea will not be used in combination with another complement inhibitor.
  3. May be used with haptoglobin less than the lower limit of normal (LLN) and presence of schistocytes
    Haptoglobin
    ThresholdLess than the lower limit of normal (LLN)
    Diagnostic useEvidence of microangiopathic hemolysis in the clinical and laboratory pathway for TA-TMA confirmation
    Related laboratory findingMay be used with serum LDH greater than the upper limit of normal (ULN) and presence of schistocytes
    Weight-Based Dosing
    50 kg or moreAdminister 370 mg as an intravenous infusion once weekly
    Less than 50 kgAdminister 4 mg/kg as an intravenous infusion once weekly
    Frequency adjustmentFrequency may increase to twice weekly if there is inadequate improvement in signs and symptoms, subject to reauthorization criteria
    Documentation Required

    Submit initial clinical documentation

    Submit chart notes documenting the member’s age, post-HSCT status, prescriber or consulting specialist, and TA-TMA diagnosis. If diagnosis is confirmed by renal or intestinal biopsy, include the biopsy documentation in the chart notes.

    • Member is at least 2 years of age
    • Post-hematopoietic stem cell transplant status
    • Prescription by or consultation with a hematologist or transplant specialist
    • TA-TMA diagnostic confirmation
    Documentation Required

    Complete required attestations

    The provider must attest that the member does not have an active infection, positive direct Coombs test, or Shiga toxin-producing Escherichia coli hemolytic uremic syndrome (STEC-HUS). The provider must also attest that Yartemlea will not be used in combination with another complement inhibitor.

    • No active infection
    • No positive direct Coombs test
    • No STEC-HUS
    • No combination therapy with another complement inhibitor
    Documentation Required

    Document response for reauthorization

    For reauthorization, submit chart notes showing improvement in platelet count and LDH levels, plus improvement in organ function or independence from transfusions. For dose escalation, document inadequate improvement in signs and symptoms.

    • Improvement in platelet count and LDH levels
    • Improvement in organ function or independence from transfusions
    • For dose escalation: inadequate improvement in signs and symptoms
    Denial Risk

    Meet eligibility and diagnostic criteria

    Coverage may be denied when the member is younger than 2 years, is not post-hematopoietic stem cell transplant, lacks the required TA-TMA diagnostic confirmation, or the medication is not prescribed by or in consultation with a hematologist or transplant specialist.

    • Member must be at least 2 years of age
    • Member must be post-HSCT
    • TA-TMA must be confirmed by renal or intestinal biopsy or the specified clinical and laboratory findings
    • Prescription must be by or in consultation with a hematologist or transplant specialist
    Denial Risk

    Avoid listed exclusions and combination therapy

    Coverage may be denied when the member has an active infection, positive direct Coombs test, or Shiga toxin-producing Escherichia coli hemolytic uremic syndrome (STEC-HUS). Coverage may also be denied if Yartemlea will be used with another complement inhibitor.

    • Active infection
    • Positive direct Coombs test
    • STEC-HUS
    • Combination with another complement inhibitor
    Denial Risk

    Use only for a listed indication

    Coverage may be denied for indications not listed in the policy. For any other indication, refer the request to the Off-Label policy.

    • Use is covered for TA-TMA under the stated criteria
    • Refer other indications to the Off-Label policy